TNF and rheumatoid arthritis: The incidence rate (IR) of serious infections in randomized controlled trials (RCTs) investigating tofacitinib, a JAKi, was similar to that in RCTs evaluating bDMARDs including TNF inhibitors (TNFis) in patients with RA [10].